Therapeutic manipulation of HDL fails to benefit adults with heart diseaseBMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e7643 (Published 13 November 2012) Cite this as: BMJ 2012;345:e7643
Dalcetrapib increases serum concentrations of high density lipoprotein (HDL) cholesterol, and Hoffmann-La Roche developed this new drug in response to observational evidence that higher concentrations were associated with a lower risk of cardiovascular disease. Dalcetrapib failed to prevent cardiovascular …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial